RDGT · Ridgetech Inc.

Could not be re-screened as of 2026-07-15 — share count for RDGT predates its balance sheet (2025-03-31 < 2025-09-30). The figures below are from the last successful run and may be stale.

Ridgetech, Inc. operates as a wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. It operates through three segments: Retail Drugstores, Online Pharmacy, and Drug Wholesale. The company engages in offline and online wholesale distribution of pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products comprising consumable, seasonal, and promotional items. It also distributes other healthcare products, such as health food, cosmetics, and daily necessities. The company was formerly known as China Jo-Jo Drugstores, Inc. and changed its name to Ridgetech, Inc. in February 2024. Ridgetech, Inc. is headquartered in Hangzhou, China.

Cap structure and valuation

Cap structure
SP	$1.50
SO	5.9M
Options	—
Warrants	—
FD SO	5.9M
MC	$8.8M

Cash	$13.9M
Total debt	$7.1M
EV	$2.0M

TTM Multiples
EV / Revenue	—
EV / EBITDA	—
MC / Net Income	—
EV / FCF	—
MC / FCF	—

Ownership & coverage
Institutional	0.2%
Insiders	1.7%
# Institutions	4
Analysts	0
Consensus	—
Avg target	—

Short % float	3.7%
Days to cover	0.01

MC = SP × FD SO. EV = MC + Debt − Cash. SP = previous yfinance close. Balance-sheet figures as of 2025-03-31. Multiples use TTM (sum of last 4 quarters); shown as "—" when the denominator is zero or negative, or when fewer than four quarters are reported — a partial sum is not a trailing twelve months. Ownership & coverage per Yahoo Finance as of 2026-07-13 — institutional % is 13F-based, so it can lag a quarter and exceed 100% on share-count timing. Short interest per FINRA bi-monthly reporting, as of 2026-06-29; the float denominator can be unreliable on tiny floats.

This filer tags no option or warrant count, so FD SO counts it as zero and understates dilution — treat FD SO, MC and EV as a floor. (XBRL reports nothing both for a filer that has none and for one that simply doesn't tag them.)

Financial statements

	3/31/26	3/31/25	3/31/24	3/31/23
Total Revenue	132.16	119.97	123.99	120.20
Revenue YoY %	10.2%	(3.2%)	3.2%	—
Cost of Revenue	127.41	116.13	119.12	116.60
Gross Profit	4.75	3.84	4.88	3.60
Gross Profit YoY %	23.8%	(21.3%)	35.5%	—
Gross Margin %	3.6%	3.2%	3.9%	3.0%

SG&A	6.62	4.87	4.28	6.40
Operating Expense	6.62	4.87	4.28	16.76

Operating Income	(1.87)	(1.04)	0.60	(13.16)
Operating Income YoY %	(80.2%)	(273.7%)	104.5%	—
Operating Margin %	(1.4%)	(0.9%)	0.5%	(11.0%)
EBITDA	(1.50)	0.10	1.39	(12.44)
EBITDA Margin %	(1.1%)	0.1%	1.1%	(10.4%)

Interest Expense	0.07	(0.09)	(0.20)	(0.03)
Other Income / (Expense)	0.58	11.65	(5.07)	(7.61)
Pretax Income	(1.35)	10.70	(4.28)	(20.74)
Tax Provision	(0.10)	0.50	(0.04)	0.39
Net Income	(1.25)	10.20	(4.23)	(21.14)
Net Income to Common	(1.25)	10.19	(4.23)	(21.14)
Net Margin %	(0.9%)	8.5%	(3.4%)	(17.6%)

Diluted EPS	-$17.21	$275.87	-$439.78	-$41.46
Basic EPS	-$17.21	$275.87	-$439.78	-$41.46
Diluted Avg Shares	0.1	0.0	0.0	0.5
Basic Avg Shares	0.1	0.0	0.0	0.5

	3/31/26	3/31/25	3/31/24	3/31/23
Cash & Equivalents	17.91	12.78	2.30	18.81
Receivables	32.47	27.81	6.01	14.12
Inventory	8.26	9.76	9.08	15.31
Other Current Assets	5.93	9.36	52.29	16.25
Total Current Assets	64.56	59.71	69.68	64.48

Net PPE	0.01	0.01	0.01	5.10
Operating Lease ROU	—	—	13.83	13.92
Goodwill	1.46	1.46	—	—
Intangible Assets	3.00	3.30	1.28	3.20
Long-term Investments	—	—	1.20	1.77
Other Assets	—	—	9.07	2.49
Total Assets	69.03	64.48	95.06	90.97

Accounts Payable	22.76	19.67	30.58	26.99
Current Lease Liabilities	—	—	35.68	5.13
Other Current Liabilities	5.14	14.69	8.10	34.41
Total Current Liabilities	27.89	34.36	74.36	66.54
Long-term Lease Liabilities	—	—	6.40	7.77
Total Liabilities	28.25	34.85	80.76	74.30

Retained Earnings	(64.56)	(63.31)	(73.51)	(69.27)
Total Equity	40.78	29.64	14.29	16.67

	6M 9/30/25	6M 9/30/24	6M 9/30/23	6M 9/30/22
Net Income	(0.06)	(2.28)	(0.92)	(0.60)
D&A	0.03	0.50	0.32	0.63
Stock-Based Comp	—	—	—	1.72
Δ Working Cap & Other	5.38	(8.18)	1.33	(0.69)
Operating Cash Flow	5.35	(9.95)	0.72	1.06

CapEx	—	(0.15)	(0.01)	(0.03)
Other Investing	—	—	(1.32)	—
Investing Cash Flow	—	(0.43)	(1.33)	(0.08)

Stock Issuance	—	7.63	2.59	1.50
Other Financing	(5.87)	—	(2.26)	(4.48)
Financing Cash Flow	(5.87)	7.83	0.33	(2.98)

Effect of FX on Cash	0.02	0.78	(1.70)	(3.21)

Free Cash Flow	—	(10.11)	0.71	1.03

Year-to-date columns, not discrete quarters — this filer reports its cash flow statement cumulatively from the start of the fiscal year and has not published two interim periods within one year that could be subtracted to isolate a quarter. Each column's span is in its heading.

	3/31/26	3/31/25	3/31/24	3/31/23
Net Income	(1.25)	10.20	(4.23)	(21.14)
D&A	0.36	1.14	0.79	0.72
Stock-Based Comp	—	—	—	10.36
Δ Working Cap & Other	(0.51)	(10.09)	0.29	6.78
Operating Cash Flow	(1.39)	1.25	(3.16)	(3.28)

CapEx	(0.00)	(0.16)	(0.33)	(0.12)
Acquisitions	—	4.83	—	—
Other Investing	—	(22.81)	(1.71)	—
Investing Cash Flow	(0.00)	(18.14)	(2.04)	(0.32)

Stock Issuance	10.88	7.63	2.59	7.33
Other Financing	(10.91)	(6.13)	5.41	(4.96)
Financing Cash Flow	(0.03)	1.51	8.00	2.37

Effect of FX on Cash	0.80	1.05	(1.51)	(2.54)

Free Cash Flow	(1.39)	1.09	(3.49)	(3.40)

	3/31/26	3/31/25	3/31/24	3/31/23
Current Ratio	2.31	1.74	0.94	0.97
Quick Ratio	2.02	1.45	0.82	0.74
Debt / Equity	—	—	—	—
EBITDA Margin %	(1.1%)	0.1%	1.1%	(10.4%)
Working Capital	36.66	25.35	(4.68)	(2.05)
Net Debt	—	—	—	—
ROE %	(3.1%)	34.4%	(29.6%)	(126.8%)
ROA %	(1.8%)	15.8%	(4.5%)	(23.2%)

Insider activity (last 2 years)

Date Filed	Reporter	Relationship	Trans. Date	Code	Shares	Price	Total Value
2026-06-11	HRT FINANCIAL LP	10% Owner	2026-06-10	P	14,312	$1.62	$23,143
2026-06-11	HRT FINANCIAL LP	10% Owner	2026-06-09	P	25,024	$1.78	$44,568